Your browser doesn't support javascript.
Sequence analysis of SARS-CoV-2 genome reveals features important for vaccine design.
Kames, Jacob; Holcomb, David D; Kimchi, Ofer; DiCuccio, Michael; Hamasaki-Katagiri, Nobuko; Wang, Tony; Komar, Anton A; Alexaki, Aikaterini; Kimchi-Sarfaty, Chava.
  • Kames J; Division of Plasma Protein Therapeutics, Office of Tissue and Advanced Therapies, Center for Biologics Evaluation and Research, Food and Drug Administration, Silver Spring, MD, USA.
  • Holcomb DD; Division of Plasma Protein Therapeutics, Office of Tissue and Advanced Therapies, Center for Biologics Evaluation and Research, Food and Drug Administration, Silver Spring, MD, USA.
  • Kimchi O; Harvard University School of Engineering and Applied Sciences, Cambridge, MA, USA.
  • DiCuccio M; National Center of Biotechnology Information, National Institutes of Health, Bethesda, MD, USA.
  • Hamasaki-Katagiri N; Division of Plasma Protein Therapeutics, Office of Tissue and Advanced Therapies, Center for Biologics Evaluation and Research, Food and Drug Administration, Silver Spring, MD, USA.
  • Wang T; Division of Viral Products, Office of Vaccines Research and Review, Center for Biologics Evaluation and Research, Food and Drug Administration, Silver Spring, MD, USA.
  • Komar AA; Center for Gene Regulation in Health and Disease, Cleveland State University, Cleveland, OH, USA.
  • Alexaki A; Division of Plasma Protein Therapeutics, Office of Tissue and Advanced Therapies, Center for Biologics Evaluation and Research, Food and Drug Administration, Silver Spring, MD, USA. Aikaterini.alexaki@fda.hhs.gov.
  • Kimchi-Sarfaty C; Division of Plasma Protein Therapeutics, Office of Tissue and Advanced Therapies, Center for Biologics Evaluation and Research, Food and Drug Administration, Silver Spring, MD, USA. Chava.kimchi-sarfaty@fda.hhs.gov.
Sci Rep ; 10(1): 15643, 2020 09 24.
Article in English | MEDLINE | ID: covidwho-796202
Preprint
This scientific journal article is probably based on a previously available preprint. It has been identified through a machine matching algorithm, human confirmation is still pending.
See preprint
ABSTRACT
As the SARS-CoV-2 pandemic is rapidly progressing, the need for the development of an effective vaccine is critical. A promising approach for vaccine development is to generate, through codon pair deoptimization, an attenuated virus. This approach carries the advantage that it only requires limited knowledge specific to the virus in question, other than its genome sequence. Therefore, it is well suited for emerging viruses, for which we may not have extensive data. We performed comprehensive in silico analyses of several features of SARS-CoV-2 genomic sequence (e.g., codon usage, codon pair usage, dinucleotide/junction dinucleotide usage, RNA structure around the frameshift region) in comparison with other members of the coronaviridae family of viruses, the overall human genome, and the transcriptome of specific human tissues such as lung, which are primarily targeted by the virus. Our analysis identified the spike (S) and nucleocapsid (N) proteins as promising targets for deoptimization and suggests a roadmap for SARS-CoV-2 vaccine development, which can be generalizable to other viruses.
Subject(s)

Full text: Available Collection: International databases Database: MEDLINE Main subject: Pneumonia, Viral / Viral Vaccines / Coronavirus Infections / Nucleocapsid Proteins / Pandemics / Spike Glycoprotein, Coronavirus / Betacoronavirus Topics: Vaccines Limits: Humans Language: English Journal: Sci Rep Year: 2020 Document Type: Article Affiliation country: S41598-020-72533-2

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: Pneumonia, Viral / Viral Vaccines / Coronavirus Infections / Nucleocapsid Proteins / Pandemics / Spike Glycoprotein, Coronavirus / Betacoronavirus Topics: Vaccines Limits: Humans Language: English Journal: Sci Rep Year: 2020 Document Type: Article Affiliation country: S41598-020-72533-2